- Home
- MNMD vs KAPA Comparison
MNMD vs KAPA Comparison
Compare MNMD & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- KAPA
- Stock Information
- Founded
- MNMD 2019
- KAPA 2013
- Country
- MNMD United States
- KAPA United States
- Employees
- MNMD 74
- KAPA N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- KAPA
- Sector
- MNMD Health Care
- KAPA
- Exchange
- MNMD Nasdaq
- KAPA NYSE
- Market Cap
- MNMD 541.7M
- KAPA N/A
- IPO Year
- MNMD N/A
- KAPA 2024
- Fundamental
- Price
- MNMD $7.02
- KAPA $0.65
- Analyst Decision
- MNMD Strong Buy
- KAPA Strong Buy
- Analyst Count
- MNMD 8
- KAPA 3
- Target Price
- MNMD $26.29
- KAPA $8.33
- AVG Volume (30 Days)
- MNMD 1.0M
- KAPA 2.1M
- Earning Date
- MNMD 08-12-2025
- KAPA 05-14-2025
- Dividend Yield
- MNMD N/A
- KAPA N/A
- EPS Growth
- MNMD N/A
- KAPA N/A
- EPS
- MNMD N/A
- KAPA N/A
- Revenue
- MNMD N/A
- KAPA N/A
- Revenue This Year
- MNMD N/A
- KAPA N/A
- Revenue Next Year
- MNMD N/A
- KAPA N/A
- P/E Ratio
- MNMD N/A
- KAPA N/A
- Revenue Growth
- MNMD N/A
- KAPA N/A
- 52 Week Low
- MNMD $4.70
- KAPA $0.40
- 52 Week High
- MNMD $10.44
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- MNMD 46.62
- KAPA N/A
- Support Level
- MNMD $6.64
- KAPA N/A
- Resistance Level
- MNMD $7.34
- KAPA N/A
- Average True Range (ATR)
- MNMD 0.45
- KAPA 0.00
- MACD
- MNMD -0.12
- KAPA 0.00
- Stochastic Oscillator
- MNMD 19.61
- KAPA 0.00
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).